Researchers at the University of Northern Colorado collected and analyzed samples of cannabis sold at several Colorado dispensaries. The findings published in PLoS One indicated that the product labels reflected a tetrahydrocannabinol (THC) potency higher than what was actually in the packaged cannabis product.
Mandates require cannabis product manufacturers to report potency (total THC % by dry weight) on the packaging, but many consumers express concern over the inaccuracy of reported THC potency values. Multiple studies have demonstrated that THC potency is a primary factor in determining cannabis flower prices. Some cannabis market experts claim there are reports of inflated THC potency and “lab shopping” to obtain higher THC potency results.
The researchers used high-performance liquid chromatography (HPLC) to analyze THC potency in 23 samples from 10 dispensaries located in the Colorado Front Range region. They compared the results to the THC potency reported on the packaging. The average observed THC potency was 14.98 +/- 2.23%, substantially lower than reports summarizing dispensary-reported THC potency. The average observed THC potency was 23.1% lower than the lowest label reported values and 35.6% lower than the highest label reported values. Overall, roughly 70% of the samples were more than 15% lower than the THC potency numbers reported on the label, and three samples had only half of the reported maximum THC potency.
Horticultural advancements in cannabis cultivation and market demand are some factors that have contributed to increased THC levels. The specific factors causing cannabinoid reporting discrepancies are difficult to pinpoint, but many cannabis experts and consumers believe the lack of standardized testing protocols, regulatory oversight shortfalls, and financial incentives to market high THC potency most likely play a significant role in THC level discrepancies. The results suggest the need to reinforce potency level accuracy. Accurate reporting of THC potency is essential for medical cannabis patients who require consistent dosage. Recreational consumers expect an effect aligned with a cannabis product price. Lack of accuracy can weaken trust in the cannabis industry as a whole.
Sources:
Eureka News Alert, PLoS One, Washington Post
